9-34485239-C-T
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP6_Very_StrongBA1
The NM_012144.4(DNAI1):c.179C>T(p.Ala60Val) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00412 in 1,614,094 control chromosomes in the GnomAD database, including 240 homozygotes. In-silico tool predicts a benign outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_012144.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DNAI1 | NM_012144.4 | c.179C>T | p.Ala60Val | missense_variant, splice_region_variant | 3/20 | ENST00000242317.9 | NP_036276.1 | |
DNAI1 | NM_001281428.2 | c.179C>T | p.Ala60Val | missense_variant, splice_region_variant | 3/20 | NP_001268357.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DNAI1 | ENST00000242317.9 | c.179C>T | p.Ala60Val | missense_variant, splice_region_variant | 3/20 | 1 | NM_012144.4 | ENSP00000242317.4 |
Frequencies
GnomAD3 genomes AF: 0.0220 AC: 3352AN: 152122Hom.: 132 Cov.: 32
GnomAD3 exomes AF: 0.00609 AC: 1531AN: 251472Hom.: 50 AF XY: 0.00410 AC XY: 557AN XY: 135910
GnomAD4 exome AF: 0.00225 AC: 3294AN: 1461854Hom.: 109 Cov.: 31 AF XY: 0.00187 AC XY: 1361AN XY: 727232
GnomAD4 genome AF: 0.0220 AC: 3353AN: 152240Hom.: 131 Cov.: 32 AF XY: 0.0211 AC XY: 1572AN XY: 74454
ClinVar
Submissions by phenotype
Primary ciliary dyskinesia Benign:4
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Benign, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 10, 2015 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
not specified Benign:2
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Dec 27, 2013 | - - |
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 28, 2020 | - - |
Likely benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Kartagener syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 06, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at